Pavan K Bhatraju1,2, Leila R Zelnick2, Michael Shlipak3, Ronit Katz2, Bryan Kestenbaum2. 1. Division of Pulmonary and Critical Care Medicine and Bhatraju@uw.edu. 2. Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington; and. 3. Kidney Health Research Collaborative, Division of Nephrology, San Francisco Veterans Affairs Medical Center and University of California, San Francisco, California.
Abstract
BACKGROUND: TNF receptor-1 (TNFR-1), which plays a causative role in endothelial cell dysfunction and inflammation, is expressed on the cell surface in glomerular and peritubular capillary endothelium of the kidneys. Higher soluble TNF receptor-1 (sTNFR-1) concentrations are associated with kidney disease progression among persons with established diabetic kidney disease. However, no studies have assessed sTNFR-1's role in long-term kidney function changes in a multiethnic population without cardiovascular disease at baseline. METHODS: We tested associations between baseline sTNFR-1 concentrations and 10-year decline in eGFR (incident ≥40% decline and annual proportional decline) among 2548 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort study. Serum creatinine concentrations were determined at enrollment and study years 3, 5, and 10. RESULTS: Mean age of participants was 61 years old, 53% were women, and mean baseline eGFR was 79 ml/min per 1.73 m2. Serum sTNFR-1 was inversely associated with baseline eGFR. Over median follow-up of 9.3 years, 110 participants developed ≥40% decline in eGFR; each SD higher concentration of sTNFR1 was associated with higher risk of 40% eGFR decline (adjusted hazard ratio, 1.43; 95% confidence interval [95% CI], 1.16 to 1.77; P<0.001). The highest sTNFR-1 tertile was associated with adjusted annualized decline in eGFR of 1.94% (95% CI, 1.79 to 2.09). Associations persisted across subgroups defined by demographics, hypertension, diabetes, and baseline CKD status. CONCLUSIONS: Elevated serum sTNFR-1 concentrations are associated with faster declines in eGFR over the course of a decade in a multiethnic population, independent of previously known risk factors for kidney disease progression.
BACKGROUND:TNF receptor-1 (TNFR-1), which plays a causative role in endothelial cell dysfunction and inflammation, is expressed on the cell surface in glomerular and peritubular capillary endothelium of the kidneys. Higher soluble TNF receptor-1 (sTNFR-1) concentrations are associated with kidney disease progression among persons with established diabetic kidney disease. However, no studies have assessed sTNFR-1's role in long-term kidney function changes in a multiethnic population without cardiovascular disease at baseline. METHODS: We tested associations between baseline sTNFR-1 concentrations and 10-year decline in eGFR (incident ≥40% decline and annual proportional decline) among 2548 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort study. Serum creatinine concentrations were determined at enrollment and study years 3, 5, and 10. RESULTS: Mean age of participants was 61 years old, 53% were women, and mean baseline eGFR was 79 ml/min per 1.73 m2. Serum sTNFR-1 was inversely associated with baseline eGFR. Over median follow-up of 9.3 years, 110 participants developed ≥40% decline in eGFR; each SD higher concentration of sTNFR1 was associated with higher risk of 40% eGFR decline (adjusted hazard ratio, 1.43; 95% confidence interval [95% CI], 1.16 to 1.77; P<0.001). The highest sTNFR-1 tertile was associated with adjusted annualized decline in eGFR of 1.94% (95% CI, 1.79 to 2.09). Associations persisted across subgroups defined by demographics, hypertension, diabetes, and baseline CKD status. CONCLUSIONS: Elevated serum sTNFR-1 concentrations are associated with faster declines in eGFR over the course of a decade in a multiethnic population, independent of previously known risk factors for kidney disease progression.
Authors: Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: P L Lutsey; M Cushman; L M Steffen; D Green; R G Barr; D Herrington; P Ouyang; A R Folsom Journal: J Thromb Haemost Date: 2006-09-26 Impact factor: 5.824
Authors: Barry I Freedman; Fang-Chi Hsu; Carl D Langefeld; Donald W Bowden; Shahriar Moossavi; Bonnie N Dryman; J Jeffrey Carr Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: Kathleen D Liu; David V Glidden; Mark D Eisner; Polly E Parsons; Lorraine B Ware; Arthur Wheeler; Anna Korpak; B Taylor Thompson; Glenn M Chertow; Michael A Matthay Journal: Crit Care Med Date: 2007-12 Impact factor: 7.598
Authors: Amelia K Boehme; Leslie A McClure; Yu Zhang; Jorge M Luna; Oscar H Del Brutto; Oscar R Benavente; Mitchell S V Elkind Journal: Stroke Date: 2016-03 Impact factor: 7.914
Authors: Chang Xu; Anthony Chang; Bradley K Hack; Michael T Eadon; Seth L Alper; Patrick N Cunningham Journal: Kidney Int Date: 2013-07-31 Impact factor: 10.612
Authors: Meda E Pavkov; E Jennifer Weil; Gudeta D Fufaa; Robert G Nelson; Kevin V Lemley; William C Knowler; Monika A Niewczas; Andrzej S Krolewski Journal: Kidney Int Date: 2016-01-04 Impact factor: 10.612
Authors: Axel C Carlsson; Toralph Ruge; Erik Kjøller; Jørgen Hilden; Hans Jørn Kolmos; Ahmad Sajadieh; Jens Kastrup; Gorm Boje Jensen; Anders Larsson; Christoph Nowak; Janus Christian Jakobsen; Per Winkel; Christian Gluud; Johan Ärnlöv Journal: J Am Heart Assoc Date: 2018-04-23 Impact factor: 5.501
Authors: Pavan Kumar Bhatraju; Leila R Zelnick; Ronit Katz; Carmen Mikacenic; Susanna Kosamo; William O Hahn; Victoria Dmyterko; Bryan Kestenbaum; David C Christiani; W Conrad Liles; Jonathan Himmelfarb; Mark M Wurfel Journal: Clin J Am Soc Nephrol Date: 2019-03-27 Impact factor: 8.237
Authors: Kinsuk Chauhan; Girish N Nadkarni; Fergus Fleming; James McCullough; Cijiang J He; John Quackenbush; Barbara Murphy; Michael J Donovan; Steven G Coca; Joseph V Bonventre Journal: Kidney360 Date: 2020-06-30
Authors: Mark J Sarnak; Ronit Katz; Joachim H Ix; Paul L Kimmel; Joseph V Bonventre; Jeffrey Schelling; Mary Cushman; Ramachandran S Vasan; Sushrut S Waikar; Jason H Greenberg; Chirag R Parikh; Steven G Coca; Venkata Sabbisetti; Manasi P Jogalekar; Casey Rebholz; Zihe Zheng; Orlando M Gutierrez; Michael G Shlipak Journal: Kidney Int Rep Date: 2022-03-25
Authors: Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet Journal: Metabolism Date: 2021-01-07 Impact factor: 8.694
Authors: Lili Chan; Girish N Nadkarni; Fergus Fleming; James R McCullough; Patricia Connolly; Gohar Mosoyan; Fadi El Salem; Michael W Kattan; Joseph A Vassalotti; Barbara Murphy; Michael J Donovan; Steven G Coca; Scott M Damrauer Journal: Diabetologia Date: 2021-04-02 Impact factor: 10.122
Authors: Teresa K Chen; Michelle M Estrella; Lawrence J Appel; Josef Coresh; Shengyuan Luo; Jochen Reiser; Wassim Obeid; Chirag R Parikh; Morgan E Grams Journal: Am J Kidney Dis Date: 2021-01-01 Impact factor: 11.072